Nuclear overexpression of MED12 was detected in 40% of patients with distant metastatic CRPC and 21% of patients with locally recurrent CRPC, whereas it was detected in fewer than 11% of patients with androgen-sensitive PCa. This evidence concerns the gene MED12 and posterior cortical atrophy.